Advice
In the absence of a submission from the holder of the marketing authorisation
bevacizumab (Avastin) in combination with paclitaxel is not recommended for first-line treatment of patients with metastatic breast cancer.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHS Scotland.
Download detailed advice24KB (PDF)
Medicine details
- Medicine name:
- bevacuzimab (Avastin)
- SMC ID:
- 387/07
- Indication:
- first-line treatment of patients with metastatic breast cancer.
- Pharmaceutical company
- Roche
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 09 July 2007